EC SME Instrument Phase 1 Grant

calendar icon June 20, 2018

SunRegen has received funding from the European Union’s SME Instrument Phase 1 program under grant agreement No 827153.

Supported By:

SunRegen Healthcare AG is a biopharmaceutical company to develop drugs for the unmet medical needs of Neurodegenerative diseases and ophthalmic diseases.

Quick Links

Contacts Info

+41 76 461 6688

SunRegen Healthcare AG
Business Parc Reinach
Christoph Merian-Ring 11, 4153 Reinach Switzerland

info@sunregen.ch